Novavax Inc. (NVAX) presented new immunogenicity data from its RSV F-Protein Nanoparticle vaccine candidate clinical trials at the 8th Vaccine & ISV Congress in Philadelphia, PA on Sunday.
Novavax gapped up at the open Monday and climbed during the final 2 hours of trade. The stock ended the day with a gain of 0.67 at $5.80, with volume at over a 4-month high. Novavax surged to a 7 1/2 month high.
For comments and feedback contact: editorial@rttnews.com
Business News